MedRx Co., Ltd
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥59M | ¥30M | ¥258M | ¥128M |
| Gross Profit | ¥57M | ¥27M | ¥258M | ¥127M |
| Operating Income | -¥1,099M | -¥934M | -¥793M | -¥942M |
| Pretax Income | -¥1,099M | -¥934M | -¥793M | -¥942M |
| Net Income | -¥1,111M | -¥933M | -¥807M | -¥937M |
| EPS | -¥43.81 | -¥26.82 | -¥18.56 | -¥17.44 |
| Operating Margin | -1,847.32% | -3,160.99% | -307.48% | -735.45% |
| Balance Sheet | ||||
| Total Assets | ¥1,398M | ¥2,052M | ¥2,276M | ¥2,158M |
| Total Equity | ¥1,213M | ¥1,925M | ¥2,170M | ¥2,049M |
| Total Liabilities | ¥186M | ¥128M | ¥106M | ¥109M |
| Cash | ¥994M | ¥1,721M | ¥1,978M | ¥1,755M |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 86.73% | 93.79% | 95.36% | 94.97% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | -¥1,073M | -¥914M | -¥803M | -¥888M |
| Investing CF | -¥2M | -¥1M | -¥3M | -¥83M |
| Financing CF | ¥356M | ¥1,639M | ¥1,067M | ¥745M |
| Free CF | -¥1,075M | -¥915M | -¥804M | -¥971M |
| Efficiency | ||||
| ROE | -91.63% | -48.47% | -37.18% | -45.75% |
| ROA | -79.47% | -45.46% | -35.45% | -43.45% |
Latest IR Information
-
Notice of Large-Scale Exercise of the 35th Stock Acquisition Rights Issued via Third-Party Allotment (with Exercise Price Adjustment Provisions)
Regarding the 1,522,200 shares issued since the beginning of the month, 15,222 stock options were exercised (10.30% of the total issued 147,820). As of now, unexercised options amount to 64,173 (6,417,300 shares). This notice discloses the specific exercise dates and...
Read more -
Notice of patent allowance for Bondlido (U.S.)
通知 of U.S. patent allowance for Bondlido. The manufacturing process technology ensuring uniformity and stability of a formulation for treating postherpetic neuralgia (PHN) is protected. The patent term extends to 2040. Considered to contribute to medium- to long-term performance improvement....
Read more -
Notice of Monthly Exercise Status of the 35th Stock Acquisition Rights issued through a Third-Party Allotment (exercise price adjustment clause)
Disclosure of the July monthly exercise status of the 35th stock acquisition rights allocated to Growth Capital. The number of issued shares is 5,936,500 shares; stock acquisition rights exercised in July total 59,365 units (40.16% of issued shares), with 7,939,500...
Read more -
Notice Regarding the Large-Scale Exercise of Stock Acquisition Rights Issued Through Third-Party Allotment with Exercise Price Adjustment Clause (2023)
Read more -
Notice Regarding Large-Scale Exercise of the 35th Warrants with Exercise Price Adjustment Clause Issued Through a Third-Party Allocation
Read more
Latest News (5 items)
Medrx Sees FY Loss Y1.20B - Moomoo ↗
Company Information
About
MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops transdermal medicines based on the ionic liquid transdermal system (ILTS) and the nano-sized colloid transdermal system (NCTS); and microneedle arrays/patch vaccines for the delivery of vaccines and APIs through the skin. Its products also include MRX-5LBT, which has NDA approval in the United States for neuropathic pain; MRX-4TZT, which is in a Phase II trial for spastic paralysis; Alto-101, which is in a Phase II trial for schizophrenia; MRX-9FLT, which is in a Phase I trial for moderate to severe pain; and MRX-6LDT, which is in a drug formulation development stage for chronic pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.